AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18806506 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical arm trainer
Number of subjects: 54
Study 18806506 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 54
Study 18806506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mechanical arm trainer and Electrical stimulation)
Number of subjects: 54
Study 15839828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamental local analgesia (ILA) with bupivicaine 0.5% and 1:200,000 adrenaline
Number of subjects: 30
Study 15839828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamental local analgesia (ILA)
Number of subjects: 30
Study 15839828 — intervention group
Group type: COMPARATOR
Intervention: Control side (no ILA)
Number of subjects: 30
Study 14759321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg, total dose < 1 g) injected once
Number of subjects: 236
Study 14759321 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/(kg.d), tid) for 10 days
Number of subjects: 236
Study 10233203 — intervention group
Group type: COMPARATOR
Intervention: 200 mg racemic ibuprofen
Number of subjects: 14
Study 10233203 — intervention group
Group type: COMPARATOR
Intervention: 600 mg racemic ibuprofen
Number of subjects: 14
Study 8942221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (750 mg i.v. 8H for 48 H/500 mg p.o bid)
Number of subjects: 48
Study 8942221 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (1.2 g i.v. 8 H for 48 H/750 mg p.o. tid)
Number of subjects: 48
Study 1763562 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (microspheres of size 1.0-1.2 mm)
Number of subjects: 10
Study 1763562 — intervention group
Group type: COMPARATOR
Intervention: Preparation B (microspheres of size 1.8-2.0 mm)
Number of subjects: 10
Study 6215932 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 75
Study 6215932 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 75
Study 6215932 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 75
Study 30742596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Preservation Technique
Number of subjects: 25
Study 30742596 — intervention group
Group type: COMPARATOR
Intervention: Tissue Reduction Technique
Number of subjects: 25
Study 28657133 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free CHX mouthrinse
Number of subjects: 80
Study 28657133 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX with antidiscoloration system (CHX-ADS)
Number of subjects: 80
Study 28657133 — intervention group
Group type: COMPARATOR
Intervention: Control group (metal-stainless steel brackets)
Number of subjects: 80
Study 26479856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 46
Study 26479856 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 46
Study 26479856 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Duration High-Intensity Interval Training (1/2HIIT)
Number of subjects: 46
Study 24755007 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC Type 2, 3, or 5 bleeding
Number of subjects: 2000
Study 24755007 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC Type 3 or 5 bleeding
Number of subjects: 2000
Study 24755007 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI criteria
Number of subjects: 2000
Study 24755007 — intervention group
Group type: EXPERIMENTAL
Intervention: GUSTO criteria
Number of subjects: 2000
Study 24755007 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 2000
Study 22678699 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 800 mg bid for 6 weeks
Number of subjects: 12
Study 22678699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22678699 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe)
Number of subjects: 12
Study 20515432 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 222
Study 20515432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 222
Study 17986636 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00915275 (15 mg)
Number of subjects: 60
Study 17986636 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-00915275 (0.3-15 mg)
Number of subjects: 60
Study 17986636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15664001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin therapy (200 IU nasal spray daily during alternate months) + 400 IU Vitamin D + 1000 mg elemental calcium
Number of subjects: 71
Study 11799482 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary portacaval shunt during the anhepatic phase
Number of subjects: 40
Study 11799482 — intervention group
Group type: COMPARATOR
Intervention: No temporary portacaval shunt
Number of subjects: 40
Study 10583020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg oral dose
Number of subjects: 0
Study 10583020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8700255 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared governance implementation
Number of subjects: 0
Study 1930053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg every 6 h)
Number of subjects: 16
Study 1930053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7091469 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker/nonsmoker segregation
Number of subjects: 0
Study 7091469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no segregation)
Number of subjects: 0
Study 31996652 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐GFR with iohexol 240
Number of subjects: 100
Study 31996652 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐GFR with iobitridol 400
Number of subjects: 100
Study 31996652 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐GFR at the renal cortex
Number of subjects: 100
Study 31996652 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐kidney CT‐GFR at ≥80 seconds after CM appearance
Number of subjects: 100
Study 31996652 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐GFR calculated using perfusion CT software with strong noise reduction
Number of subjects: 100
Study 31996652 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐GFR calculated using perfusion software with medium noise reduction
Number of subjects: 100
Study 28741660 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitative behavior of human children
Number of subjects: 77
Study 28741660 — intervention group
Group type: COMPARATOR
Intervention: Imitative behavior of bonobos
Number of subjects: 77
Study 26845453 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (Pdi,twc assessment every 45 s)
Number of subjects: 17
Study 26845453 — intervention group
Group type: COMPARATOR
Intervention: Normobaric hypoxia (SpO2 80%, Pdi,twc assessment every 45 s)
Number of subjects: 17
Study 25466568 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA (dual-source CT angiography)
Number of subjects: 562
Study 25466568 — intervention group
Group type: COMPARATOR
Intervention: ExECG (exercise stress ECG)
Number of subjects: 562
Study 22014374 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria, pathogenic protozoan and hookworm infections at baseline
Number of subjects: 904
Study 22014374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline vitamin D (<32 ng/ml) concentrations
Number of subjects: 904
Study 22014374 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline erythrocyte sedimentation rate and CD8 T-cell concentrations, lower Hb concentrations and CD4 T-cell counts
Number of subjects: 904
Study 20524441 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted intracapsular tonsillectomy (MT)
Number of subjects: 40
Study 20524441 — intervention group
Group type: COMPARATOR
Intervention: Cold instrument dissection tonsillectomy (CT)
Number of subjects: 40
Study 16905572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (2.5 mg/kg/day) and progesterone (22.5 mg/kg/day) given by continuous intravenous infusion of a standard lipid emulsion (15 ml/kg/day)
Number of subjects: 83
Study 16905572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same lipid emulsion without oestradiol or progesterone)
Number of subjects: 83
Study 16905572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol and progesterone (according to protocol)
Number of subjects: 83
Study 16244006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound
Number of subjects: 50
Study 16244006 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebos)
Number of subjects: 50
Study 11952769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril) 32 or 56 mg daily
Number of subjects: 554
Study 11952769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 10374370 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (Art) - 6 mg/kg, administered every 15 days if continued exposure, with an additional dose 7-15 days after withdrawal from pilot.
Number of subjects: 99
Study 10374370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 99
Study 7667188 — intervention group
Group type: EXPERIMENTAL
Intervention: u‐hFSH 75 IU iv
Number of subjects: 12
Study 7667188 — intervention group
Group type: EXPERIMENTAL
Intervention: u‐hFSH 150 IU iv
Number of subjects: 12
Study 7667188 — intervention group
Group type: EXPERIMENTAL
Intervention: u‐hFSH 300 IU iv
Number of subjects: 12
Study 7667188 — intervention group
Group type: EXPERIMENTAL
Intervention: u‐hFSH 150 IU im
Number of subjects: 12
Study 2765151 — intervention group
Group type: EXPERIMENTAL
Intervention: Op-site dressing
Number of subjects: 0
Study 2765151 — intervention group
Group type: COMPARATOR
Intervention: Other treatment methods
Number of subjects: 0
Study 1102887 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivastal (1 dragee daily, increasing to 3-6 dragees over 14 weeks)
Number of subjects: 66
Study 1102887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31226197 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontally Accelerated Osteogenic Orthodontics (PAOO) followed by orthodontic fixed mechanotherapy
Number of subjects: 2
Study 31226197 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic fixed mechanotherapy alone
Number of subjects: 2
Study 27416014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention
Number of subjects: 112
Study 25039499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Transit Time (MTT) thresholds of ≥ 7 seconds
Number of subjects: 0
Study 25039499 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative MTT thresholds of ≥ 125%
Number of subjects: 0
Study 25039499 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay Time (DT) thresholds of ≥ 2 seconds
Number of subjects: 0
Study 25039499 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute MTT thresholds of 8 seconds
Number of subjects: 0
Study 25039499 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative MTT thresholds of 125%
Number of subjects: 0
Study 25039499 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Cerebral Blood Flow (CBF) thresholds of ≤ 45%
Number of subjects: 0
Study 22662394 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy interventions
Number of subjects: 105
Study 22662394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 20837359 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel + cisplatin (PC)
Number of subjects: 434
Study 20837359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine + cisplatin (VC)
Number of subjects: 434
Study 20837359 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + cisplatin (GC)
Number of subjects: 434
Study 20837359 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan + cisplatin (TC)
Number of subjects: 434
Study 19041475 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-LASIK
Number of subjects: 56
Study 19041475 — intervention group
Group type: COMPARATOR
Intervention: off-flap Epi-LASIK
Number of subjects: 56
Study 19041475 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-LASIK and off-flap Epi-LASIK
Number of subjects: 56
Study 16626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology in group 1 (PEXG)
Number of subjects: 143
Study 16626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology in group 2 (PEX)
Number of subjects: 143
Study 16626422 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival impression cytology in group 3 (normal subjects)
Number of subjects: 143
Study 16626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film break-up time (TFBUT) in group 1 (PEXG)
Number of subjects: 143
Study 16626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film break-up time (TFBUT) in group 2 (PEX)
Number of subjects: 143
Study 16626422 — intervention group
Group type: COMPARATOR
Intervention: Tear film break-up time (TFBUT) in group 3 (normal subjects)
Number of subjects: 143
Study 16626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal Schirmer test (BST) in group 1 (PEXG)
Number of subjects: 143
Study 16626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal Schirmer test (BST) in group 2 (PEX)
Number of subjects: 143
Study 16626422 — intervention group
Group type: COMPARATOR
Intervention: Basal Schirmer test (BST) in group 3 (normal subjects)
Number of subjects: 143
Study 12823236 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial OGTT 2-hour blood glucose level
Number of subjects: 108
Study 12823236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness
Number of subjects: 108
Study 12823236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness after adjustment for 2-hour blood glucose levels
Number of subjects: 108
Study 10967266 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (30 mg pamidronate IV every 3 months, n = 14)
Number of subjects: 42
Study 10967266 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (n = 10)
Number of subjects: 42
Study 10967266 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (n = 5)
Number of subjects: 42
Study 10967266 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (pamidronate or HRT)
Number of subjects: 42
Study 8829118 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion alone
Number of subjects: 8
Study 8829118 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide infusion alone
Number of subjects: 8
Study 8829118 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide and dopamine infusions administered concurrently
Number of subjects: 8
Study 8829118 — intervention group
Group type: COMPARATOR
Intervention: Dopamine, Furosemide, or their coadministration
Number of subjects: 8
Study 7949627 — intervention group
Group type: EXPERIMENTAL
Intervention: TBARM in ALI patients (3.05 +/‐ 0.65 nMol/ml)
Number of subjects: 21
Study 7949627 — intervention group
Group type: EXPERIMENTAL
Intervention: 7S collagen in ALI patients (9.06 +/‐ 5.96 ng/ml)
Number of subjects: 21
Study 7949627 — intervention group
Group type: EXPERIMENTAL
Intervention: TBARM levels in deceased ALI patients
Number of subjects: 21
Study 7949627 — intervention group
Group type: EXPERIMENTAL
Intervention: 7S collagen levels in deceased ALI patients
Number of subjects: 21
Study 3228992 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthetic (LA)
Number of subjects: 29
Study 3228992 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthetic (GA)
Number of subjects: 29
Study 30476603 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill CPET
Number of subjects: 24
Study 30476603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bike CPET
Number of subjects: 24
Study 28869989 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 2
Study 28869989 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 2
Study 27045252 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaprost
Number of subjects: 0
Study 27045252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 27045252 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaprost + Pregabalin
Number of subjects: 0
Study 23386159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) bupivacaine
Number of subjects: 48
Study 23386159 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) pethidine
Number of subjects: 48
Study 20959965 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial evaluation and treatment of fall risk factors
Number of subjects: 217
Study 20959965 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 217
Study 19448228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Number of subjects: 70
Study 19448228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17098764 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study 15659895 — intervention group
Group type: EXPERIMENTAL
Intervention: 24F Re‐entry tube
Number of subjects: 60
Study 15659895 — intervention group
Group type: EXPERIMENTAL
Intervention: 8F pigtail catheter
Number of subjects: 60
Study 15659895 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐J stent
Number of subjects: 60
Study 11443565 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 load 2 years after seroconversion
Number of subjects: 22
Study 11443565 — intervention group
Group type: EXPERIMENTAL
Intervention: Change over time (slope) of HIV-1 load
Number of subjects: 22
Study 11443565 — intervention group
Group type: EXPERIMENTAL
Intervention: Early virus loads
Number of subjects: 22
Study 11443565 — intervention group
Group type: EXPERIMENTAL
Intervention: Slopes of virus load
Number of subjects: 22
Study 11443565 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher early virus loads
Number of subjects: 22
Study 11443565 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher slopes of virus load
Number of subjects: 22
Study 9118614 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF 300 U/d on days 8 and 15 post-chemotherapy for neutropenia prophylaxis
Number of subjects: 34
Study 9118614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GM-CSF)
Number of subjects: 34
Study 1999086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 300 mg i.v. every 12 hours for pneumonia
Number of subjects: 31
Study 1999086 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g i.v. every eight hours for pneumonia
Number of subjects: 31
Study 1999086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg i.v. every 12 hours for UTI
Number of subjects: 31
Study 1999086 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 1 g i.v. every eight hours for UTI
Number of subjects: 31
Study 6465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 6465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 10
Study 6465021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31690602 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (2-year duration, 2 weekly sessions: 5 min warm-up, 20 min aerobic training, 30 min resistance training, 20 min core stability, balance and flexibility training with weighted vests)
Number of subjects: 200
Study 31690602 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 31690602 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 200
Study 28743399 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (three educational sessions)
Number of subjects: 320
Study 28743399 — intervention group
Group type: COMPARATOR
Intervention: Control group (informative leaflet)
Number of subjects: 320
Study 25746777 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐administered mCBT‐I (n=20; 6 short booklets + 3 phone consultations with a psychologist, over 6 weeks)
Number of subjects: 38
Study 25746777 — intervention group
Group type: COMPARATOR
Intervention: no‐treatment condition (n=18)
Number of subjects: 38
Study 23403498 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d) with hormone therapy (HT)
Number of subjects: 139
Study 23403498 — intervention group
Group type: COMPARATOR
Intervention: Placebo with hormone therapy (HT)
Number of subjects: 139
Study 21788220 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride 2 mg/kg per day divided 3 times daily for 6 months
Number of subjects: 40
Study 21788220 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral solution
Number of subjects: 40
Study 19019932 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost/timolol maleate fixed combination (TTFC)
Number of subjects: 32
Study 19019932 — intervention group
Group type: COMPARATOR
Intervention: Travoprost
Number of subjects: 32
Study 19019932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 32
Study 17569958 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCTA
Number of subjects: 237
Study 17569958 — intervention group
Group type: COMPARATOR
Intervention: US‐ECD
Number of subjects: 237
Study 15007574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G
Number of subjects: 24
Study 15007574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11172508 — intervention group
Group type: COMPARATOR
Intervention: Lateral decubitus position (group I)
Number of subjects: 70
Study 11172508 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (group II)
Number of subjects: 70
Study 9728835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 150 microg
Number of subjects: 16
Study 9728835 — intervention group
Group type: COMPARATOR
Intervention: Intravenous clonidine 50 or 150 microg
Number of subjects: 16